
Adipogen/Orlistat/AG-CN2-0050-M050/50 mg
商品编号:
AG-CN2-0050-M050
品牌:
Adipogen Inc
市场价:
¥600.00
美元价:
360.00
产品分类:
其他试剂
公司分类:
Other_reagents
联系Q Q:
3392242852
电话号码:
4000-520-616
电子邮箱:
info@ebiomall.com
商品介绍
Product Details | |
---|---|
Synonyms | Tetrahydrolipstatin; Xenical; Alli; Ro-18-0647 |
Product Type | Chemical |
Properties | |
Formula | C29H53NO5 |
MW | 495.7 |
Merck Index | 14: 6869 |
CAS | 96829-58-2 |
Source/Host Chemicals | Synthetic. Originally isolated from Streptomyces sp. |
Purity Chemicals | ≥98% (HPLC) |
Appearance | White to off-white solid. |
Solubility | Soluble in DMSO, ethanol or DMF. |
Identity | Determined by HPLC and IR. |
InChi Key | AHLBNYSZXLDEJQ-FWEHEUNISA-N |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice |
After reconstitution, prepare aliquots and store at -20°C. Protect from light and moisture. |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS |
![]() |
Product Specification Sheet | |
Datasheet |
![]() |
- Hypolipemic cell permeable and irreversible pancreatic, gastric and carboxylester lipase inhibitor [1-3].
- Anti-obesity and antihypercholesterolemic compound [2, 5, 11].
- Antitumor compound by inhibition of the thioesterase domain of fatty acid synthase (FASN) [4, 6, 9, 10].
- Anti-proliferative [4, 6, 9, 10].
- Causes cell cycle arrest at G1 phase. Apoptosis inducer through caspase-3 activation [6, 10].
- Sn-1-selective-diacylglycerol lipases α (DAGLα) inhibitor. Targets serine hydrolases in the nervous system, such as diacylglycerol lipase (DAGL), which is responsible for the conversion of DAG to 2-AG [7].
- Partially inhibits the hydrolysis of triglycerides and lowers the absorption of dietary fat, promoting weight loss [8].
- Promotes the sensitivity to TRAIL in cancer cells by ROS-mediated pathways [11].
Product References
- Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat): A. Lookene, et al.; Eur. J. Biochem. 222, 395 (1994)
- Mode of action of orlistat: R. Guerciolini; Int. J Obes. Relat. Metab. Disord. 2, S12 (1997) (Review)
- Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine: B. Sternby, et al.; Clin. Nutr. 21, 395 (2002)
- Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity: S.J. Kridel, et al.; Cancer Res. 64, 2070 (2004)
- The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes: R.H. Nelson & J.M. Miles; Expert Opin. Pharmacother. 6, 2483 (2005) (Review)
- Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene: J.A. Menendez, et al.; Ann. Oncol. 16, 1253 (2005)
- Development of the first potent and specific inhibitors of endocannabinoid biosynthesis: T. Bisogno, et al.; Biochim. Biophys. Acta 1761, 205 (2006)
- Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects: F.Y. Enc, et al.; Am. J. Physiol. Gastrointest. Liver Physiol. 296, G482 (2008)
- Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model: M.A. Carvalho, et al.; Int. J. Cancer. 123, 2557 (2008)
- Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal: H.Y. Chuang, et al.; Biomed. Pharmacother. 65, 286 (2011)
- The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells: J. Fujiwara, et al.; Int. J. Oncol. 48, 854 (2016)
品牌介绍
Adipogen公司由三个子公司组成,分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国,运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发,如癌症、免疫、炎症、代谢疾病(糖尿病、肥胖)、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外,也可提供抗体和蛋白产品,Adipogen拥有自己的化学实验室,致力于开发创新型小分子化合物。
联络我们